Sign In
Buy LPTX
$0.690
+0 (+0%)
At Close: Jun 23, 2026
Horizon (HZNP) Gets FDA Nod for Krystexxa's Label Expansion
03:58pm, Monday, 11'th Jul 2022 Zacks Investment Research
The FDA approves Horizon's (HZNP) sBLA for Krystexxa injection plus methotrexate to help people suffering from uncontrolled gout achieve a complete response to therapy.
Zacks.com featured highlights include Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics and Oncolytics Biotech
10:19am, Monday, 11'th Jul 2022 Zacks Investment Research
Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics, and Oncolytics Biotech are part of Zacks Screen of the week article.
Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug
03:48pm, Friday, 08'th Jul 2022 Zacks Investment Research
Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.
Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why
03:14pm, Friday, 08'th Jul 2022 Zacks Investment Research
The recent setback faced by Acadia's (ACAD) resubmitted sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with ADP has hurt the stock.
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
11:52am, Friday, 08'th Jul 2022 Zacks Investment Research
Want to try an out-of-the-box approach? Tap Oncolytics Biotech (ONCY), Pediatrix Medical Group Inc (MD), Boot Barn (BOOT), Canada Goose (GOOS) and Leap Therapeutics (LPTX).
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
09:20am, Friday, 08'th Jul 2022
Want to try an out-of-the-box approach? Tap Oncolytics Biotech (ONCY), Pediatrix Medical Group Inc (MD), Boot Barn (BOOT), Canada Goose (GOOS) and Leap Therapeutics (LPTX).
Adverum (ADVM) Completes IND Amendment for Gene Therapy Study
03:22pm, Thursday, 07'th Jul 2022 Zacks Investment Research
Adverum (ADVM) completes IND amendment with the FDA for initiating the phase II LUNA study on its gene therapy candidate, ADVM-022, for treating wet-age-related macular degeneration. Stock up.
Vertex (VRTX) VX-880 Early Study Sees Lifting of Clinical Hold
02:52pm, Wednesday, 06'th Jul 2022 Zacks Investment Research
The FDA lifts clinical hold on Vertex's (VRTX) study on VX-880, its stem-cell-derived, fully differentiated islet replacement therapy that could offer a functional cure for type 1 diabetes patients.
Celldex (CLDX) Down on Interim Data From Phase Ib Study in CSU
03:49pm, Monday, 04'th Jul 2022 Zacks Investment Research
Celldex (CLDX) posts interim data from the phase Ib study evaluating barzolvolimab in patients with moderate to severe chronic spontaneous urticaria. Shares down.
Seagen (SGEN) Up More Than 20% in Past 3 Months: Here's Why
04:44pm, Wednesday, 29'th Jun 2022 Zacks Investment Research
Seagen (SGEN) is riding on the strong uptake of its marketed drugs that are approved for different cancer indications. Further label expansion of these drugs should boost the top line.
Graybug (GRAY) to Review Strategic Alternatives, Stock Up
04:34pm, Wednesday, 29'th Jun 2022 Zacks Investment Research
Graybug's (GRAY) board of directors is set to review strategic options focused on maximizing shareholder value, including a potential sale of the company. Shares rise.
Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD
03:52pm, Tuesday, 28'th Jun 2022 Zacks Investment Research
Cybin (CYBN) receives a "may proceed letter" and IND application clearance from the FDA for a phase I/IIa study evaluating CYB003 for potential treatment of major depressive disorder. Shares up.
Leap Therapeutics: 2 Catalysts With Cancer Drug DKN-01 In The 2nd Half Of 2022
02:58pm, Monday, 27'th Jun 2022
Positive results using DKN-01 plus chemotherapy for the treatment of patients with metastatic castration-resistant prostate cancer were presented at ASCO 2022 medical conference. The global prostate c
uniQure (QURE) Up on Safety Data From Huntington's Disease Study
02:30pm, Friday, 24'th Jun 2022 Zacks Investment Research
uniQure (QURE) posts safety and biomarker data from the 10 patients enrolled in the lower-dose cohort of its ongoing phase I/II study evaluating AMT-130 for treating Huntington's disease.
Precision BioSciences' (DTIL) Stock Up This Week: Here's Why
04:08pm, Thursday, 23'rd Jun 2022 Zacks Investment Research
Shares of Precision BioSciences (DTIL) are up as the company inks a gene-editing deal with Novartis to develop a potentially curative treatment for disorders like sickle cell disease.
